Abbott-Angle collaboration announcement
On February 6, Angle, a London-based liquid biopsy company, announced that it was entering a collaboration with Abbott Laboratories (ABT) on a metastatic breast cancer study. Abbott Laboratories plans to provide its proprietary PathVysion HER-2 (human epidermal growth factor receptor 2) DNA (Deoxyribonucleic acid) FISH (fluorescence in situ hybridization) probe kits as a research grant to Angle PLC, which then plans to use the kits for CTC (circulating tumor cells) analysis.
The study aims to assess Angle’s Parsortix technology, which uses blood samples to harvest tumor cells to determine patients’ HER2 status using FISH analysis. The HER2 gene makes HER2 proteins, which can cause abnormal growth of breast cancer cells. If a patient’s HER2 status is positive, it implies that the HER2 gene is aiding the growth of cancer cells. Such cancers are more likely to spread and relapse than HER2-negative cancers.
The FISH analysis is a procedure for determining the HER2 status that uses a solid tissue biopsy. The procedure is invasive. However, if Angle’s study is successful, the process would become less invasive through blood tests.
As per the terms of the agreement, Abbott has the first option for the negotiation of an exclusive license for the assessment of HER2 status using Parsortix technology.